Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer

被引：111

作者：

Zhang, Jing ^{[1
,3
]}

Roberts, Thomas M. ^{[1
,3
]}

Shivdasani, Ramesh A. ^{[2
,4
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA

[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[3] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA

[4] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

来源：

GASTROENTEROLOGY | 2011年 / 141卷 / 01期

关键词：

Colon Cancer; Neoplasm; Signal Transduction; Genetics; Tumor; ISLAND METHYLATOR PHENOTYPE; TYROSINE KINASE INHIBITORS; 3-KINASE CATALYTIC SUBUNIT; PIK3CA GENE-MUTATIONS; GROWTH IN-VITRO; PHOSPHOINOSITIDE; 3-KINASE; PHOSPHATIDYLINOSITOL; COLON-CANCER; MICROSATELLITE INSTABILITY; P110-ALPHA ISOFORM;

D O I：

10.1053/j.gastro.2011.05.010

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Survival times of patients with colorectal cancer (CRC) have increased over the past decade, primarily as a result of treatment with combinations of conventional cytotoxic agents. Because CRC is commonly associated with mutations in genes that control growth factor signaling, therapies are being developed to target the products of these genes; individualized treatment might also be guided by specific mutations in tumors and by new biomarkers. Currently, targeted therapies confer limited clinical benefit; better drugs are therefore needed. Genomic studies indicate that phosphoinositide 3-kinase (PI3K) signaling is one of the most frequently deregulated pathways in several human cancers, including CRC. PI3K signaling has an important role in cancer cell proliferation, survival, motility, and metabolism and therefore could be an attractive therapeutic target. We review PI3K signaling in CRC and discuss current therapeutic approaches.

引用

页码：50 / 61

页数：12

共 120 条

[61] In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316 [J].

Meuillet, EJ ;

Ihle, N ;

Baker, AF ;

Gard, JM ;

Stamper, C ;

Williams, R ;

Coon, A ;

Mahadevan, D ;

George, BL ;

Kirkpatrick, L ;

Powis, G .

ONCOLOGY RESEARCH, 2004, 14 (10) :513-527

[62] Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit [J].

Miled, Nabil ;

Yan, Ying ;

Hon, Wai-Ching ;

Perisic, Olga ;

Zvelebil, Marketa ;

Inbar, Yuval ;

Schneidman-Duhovny, Dina ;

Wolfson, Haim J. ;

Backer, Jonathan M. ;

Williams, Roger L. .

SCIENCE, 2007, 317 (5835) :239-242

[63] Mutations of the PIK3CA gene in hereditary colorectal cancers [J].

Miyaki, Michiko ;

Iijima, Takeru ;

Yamaguchi, Tatsuro ;

Takahashi, Keiichi ;

Matsmnoto, Hiroshi ;

Yasutome, Michiya ;

Funata, Nobuaki ;

Mori, Takeo .

INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (07) :1627-1630

[64] Phosphatidylinositol 3-Kinase Signaling Does Not Activate the Wnt Cascade [J].

Ng, Ser Sue ;

Mahmoudi, Tokameh ;

Danenberg, Esther ;

Bejaoui, Ines ;

de Lau, Wim ;

Korswagen, Hendrik C. ;

Schutte, Mieke ;

Clevers, Hans .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (51) :35308-35313

[65] Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1 [J].

Niu, Q ;

Perruzzi, C ;

Voskas, D ;

Lawler, J ;

Dumont, DJ ;

Benjamin, LE .

CANCER BIOLOGY & THERAPY, 2004, 3 (04) :402-405

[66] PIK3CA mutation in colorectal cancer:: Relationship with genetic and epigenetic alterations [J].

Nosho, Katsuhiko ;

Kawasaki, Takako ;

Ohnishi, Mutsuko ;

Suemoto, Yuko ;

Kirkner, Gregory J. ;

Zepf, Dimity ;

Yan, Liying ;

Longtine, Janina A. ;

Fuchs, Charles S. ;

Ogino, Shuji .

NEOPLASIA, 2008, 10 (06) :534-541

[67] mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt [J].

O'Reilly, KE ;

Rojo, F ;

She, QB ;

Solit, D ;

Mills, GB ;

Smith, D ;

Lane, H ;

Hofmann, F ;

Hicklin, DJ ;

Ludwig, DL ;

Baselga, J ;

Rosen, N .

CANCER RESEARCH, 2006, 66 (03) :1500-1508

[68] PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer [J].

Ogino, Shuji ;

Nosho, Katsuhiko ;

Kirkner, Gregory J. ;

Shima, Kaori ;

Irahara, Natsumi ;

Kure, Shoko ;

Chan, Andrew T. ;

Engelman, Jeffrey A. ;

Kraft, Peter ;

Cantley, Lewis C. ;

Giovannucci, Edward L. ;

Fuchs, Charles S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1477-1484

[69]

Okami K, 1998, CANCER RES, V58, P509

[70]

Okkenhaug K, 2002, SCIENCE, V297, P1031

← 2 3 4 5 6 7 8 9 10 11 →